Yes there is not much value in a drug with only cardioprotection, but a drug with broad anticancer activity that is cardioprotective is very valuable. This is explained in detail in the Triangle report.
These drug that were sold off by Clinigen are all generics - the margins on generics are very low and the competition intense.
General Comments / Chat, page-9520
-
- There are more pages in this discussion • 1,522 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.63 |
Change
-0.115(6.59%) |
Mkt cap ! $285.2M |
Open | High | Low | Value | Volume |
$1.78 | $1.78 | $1.63 | $181.0K | 106.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1288 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 1400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 541 | 1.630 |
3 | 5000 | 1.625 |
1 | 20000 | 1.620 |
1 | 3165 | 1.610 |
3 | 6400 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.650 | 1427 | 1 |
1.655 | 702 | 2 |
1.660 | 2850 | 2 |
1.665 | 1400 | 1 |
1.670 | 1100 | 1 |
Last trade - 14.27pm 03/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online